CAH Gains More Than 29% in 4 Months: Will the Uptrend Continue?
Cardinal Health (CAH) shares rose 29.3% over four months, driven by strong earnings from specialty businesses. Q4 2026 revenue increased 6% to $63.7B, with operating earnings up 30% to $935M. The company expects 3-5% pharma revenue growth in 2027 but 8-11% segment profit growth. Specialty business grew 25% in 2026, and acquisitions like Solaris are boosting growth. CAH trades at a forward P/E of 18.41X, above its 5-year median but below the S&P 500's 19.83X.
How this was made
The 30-second read
Why it matters
Earnings beat and guidance raise expectations for continued specialty growth, supporting a bullish stance.
Market read
Large‑cap earnings release with material profit growth; likely to move the stock and influence sector sentiment.
What to watch
Tariff benefits may be offset by rising fuel and commodity costs, potentially narrowing profit margins.
Background
Cardinal Health's FY2026 results and FY2027 outlook were released after the market close, providing fresh data for traders.
Ticker impact
Cardinal Health reported FY2026 earnings with 30% operating earnings growth and raised FY2027 profit guidance, a fresh primary disclosure.
upside pressure in the near term as investors price in higher margins and specialty growth.
Large‑cap earnings beat with double‑digit profit growth and forward P/E below market suggest valuation still attractive.
Market effects
Positive for healthcare distribution and specialty services sector, may lift peers.
U.S. healthcare stocks could see modest gains.
Limited to U.S. market; no direct global macro effect.
Counterpoint
Valuation remains above five‑year median; any slowdown in specialty growth could pressure the stock.
Key entities
- companyCardinal Health
U.S. healthcare distribution and specialty services firm.
